China, Sept. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled '16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600131976
Registration Time: 2026/09/08
Type: Interventional study
Primary Sponsor: The Second Affiliated Hospital Zhejiang University School of Medicine
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=339269
Published by HT Digital Content Services with permission from Health Daily Digest....